Africa: Major funding boost for pediatric ARVs

Pharmaceutical company GlaxoSmithKline (GSK) has announced plans to invest up to US$97 million over 10 years in improving antiretroviral (ARV) treatment for children and adults in sub-Saharan Africa. The world's second largest drug manufacturer has pledged $16 million in seed funding to a public-private partnership that will develop new paediatric formulations of ARV drugs, GSK said in a statement this week.